subscribeSubscribe
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
PM LIVE
05 Sep 2023
Share Share
Chiesi Farmaceutici`s Elfabrio (Pegunigalsidase alfa) Receives Approval in the Europe

Chiesi Farmaceutici`s Elfabrio (Pegunigalsidase alfa) Receives Approval in the Europe
EMA
25 May 2023
Share Share
Chiesi`s Biologic Elfabrio (Pegunigalsidase alfa) Receives Approval in the U.S.

Chiesi`s Biologic Elfabrio (Pegunigalsidase alfa) Receives Approval in the U.S.
FDA
09 May 2023
Share Share
Protalix & Chiesi gain positive opinion for pegunigalsidase alfa

Protalix & Chiesi gain positive opinion for pegunigalsidase alfa
John Pinching PHARMATIMES
06 Mar 2023
Share Share
CHMP recommends first pegylated enzyme for Fabry disease

CHMP recommends first pegylated enzyme for Fabry disease
EUROPEAN PHARMACEUTICAL REVIEW
27 Feb 2023
Share Share
Chiesi & Protalix Receive Positive CHMP Opinion for Pegunigalsidase Alfa

Chiesi & Protalix Receive Positive CHMP Opinion for Pegunigalsidase Alfa
BIOSPACE
25 Feb 2023
Share Share
Protalix & Chiesi Announce FDA Acceptance of BLA for Pegunigalsidase Alfa

Protalix & Chiesi Announce FDA Acceptance of BLA for Pegunigalsidase Alfa
PRNEWSWIRE
05 Dec 2022
Share Share
Chiesi and Protalix announce Phase III data from BRIGHT study in Fabry disease

Chiesi and Protalix announce Phase III data from BRIGHT study in Fabry disease
THEPHARMALETTER
19 Mar 2022
Share Share
Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022

Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022
PRNEWSWIRE
03 Feb 2022
Share Share
Protalix sees a path for Fabry resubmission down the line

Protalix sees a path for Fabry resubmission down the line
Annalee Armstrong FIERCEBIOTECH
11 Oct 2021
Share Share